5th Annual

WORLD BIOSIMILAR CONGRESS EUROPE 2016

14-15 November 2016

Congress Centre, Basel, Switzerland

Cost-effective biologics for payers, prescribers and patients

CO-LOCATED WITH

EUROPEAN ANTIBODY CONGRESS 2016

WORLD HPAPI CONGRESS 2016

WORLD IMMUNOTHERAPY CONGRESS 2016

CREATED BY

terrapinn
use your brain

PART OF

totalbiopharma

PARTNERED WITH

Basel

terrapinn.com/biosimilar16

WHAT IS THE WORLD BIOSIMILAR CONGRESS?

A commercially focused event bringing together the full value chain and located in one of the world's major life science hubs, Basel.

Consisting of thought-leaders from across the globe, World Biosimilar Congress looks at commercialising and pushing forward the adoption of biosimilars globally. Over the last 5 years, the Congress has built up a reputation for delivering high level content and bringing together the senior executives from sourcing through to patient. It is co-located with the European Antibody Congress, World Immunotherapy Congress, and HPAPI World Congress.

Want to get involved? Register your place today at **terrapinn.com/biosimilar16**

10 REASONS TO ATTEND

1. **One event, the whole value chain in attendance** – once again, World Biosimilar Congress will bring together everyone from pharma to patient and all in between, to enable you to meet and network with the entire supply chain.

2. Engage with industry leading speakers representing companies including **Alliance for Safe Biologic Medicines, Biogen, Boehringer Ingelheim, Centre Hospitalier Universitaire Vaudois, Cinfa Biotech GmbH, Express Scripts, Merck, NDA Regulatory Science, NICE, Norwegian Medicines Agency, PAREXEL, Sandoz, Sterne, Kessler, Goldstein & Fox** and **TWC Pharma Consulting.**

3. **A truly global event,** with speakers confirmed from UK, Norway, Italy, Germany, Switzerland, France, Spain, and USA, to name but a few.

4. Meet new industry contacts at the **Speed Networking** session, sponsored by **Myoderm** - a fun, exciting and effective way to make a lot of initial connections (in a very different environment from the standard business networking meetings).

5. **Consistently leading scientific content** on preclinical and clinical development upon which this conference was born and is known for.

6. **Focus sessions on healthcare uptake:** hear from patient groups and clinicians on market access, value and pricing, extrapolation and interchangeability.

7. Panel discussions, allowing you to get involved in the discussions, on **'The Pricing Debate', 'The Indication Extrapolation Conundrum',** and **'What are the mechanics required behind the implementation of biosimilars in the market?'**

8. **Roundtable session, focusing on global success stories** from across the industry. With 2 rotations, you can attend 2 roundtables of your choice enabling you to engage in informal discussions on topics pertinent to your business.

9. **Profitable networking opportunities** across the two days with long lunch periods, ideal for business lunches, refreshment breaks, for making new contacts, and the evening drinks receptions, to strengthen existing connections.

10. Vast **business development opportunities** within the shared exhibition hall, **co-located with European Antibody Congress, High Potency API World Congress** and the new **World Immunotherapy Congress.**

Want to get involved? Register your place today at **terrapinn.com/biosimilar16**

"THIS IS AN EXCELLENT STRATEGIC CONFERENCE ON THE GLOBAL DEVELOPMENT OF BIOSIMILARS AND SHOULD BE ATTENDED BY ANYONE DEVELOPING BIOSIMILARS."

SENIOR CONSULTANT | **N.D.A. REGULATORY SCIENCE LTD**

Bernd Liedert

Sr.Clinical Program Leader Biosimilars
Boehringer Ingelheim

Dr. Liedert is currently working at Boehringer Ingelheim, prior to this he was holding a director position at Merck Serono, serving as Head of Immunopharmacology. He was member of the strategy implementation group, which established the Merck Serono´s Biosimilars Unit in 2012. He was a permanent member of the corporate Biosimilars Strategy and Policy Committee. In parallel, Dr. Liedert was involved in Merck´s innovator program, especially in the field of monoclonal antibodies.
Dr. Liedert got insight experience of the Health Authorities´ perspective, when he worked as senior regulator at the Paul-Ehrlich-Institute (PEI), the German Federal Agency for biologics and at the EMA, where he represented Germany in the Safety Working Party. He was co-author of several guidelines, which focus on risk mitigation for early clinical trials, immunogenicity and comparability/biosimilarity exercises.

Mark McCamish

Head of Global Biopharmaceutical & Oncology Injectables Development
Sandoz

Mark leads R&D of all biologics at Sandoz Biopharmaceuticals, which is the world leader in development and commercialization of biosimilars. He led the submission and approval of the first biosimilar approved by the US FDA (Zarxio) with a 14:0 Oncology Drug Advisory Committee recommendation. His responsibilities include oversight of cloning, technical development, scale-up, pre-clinical and clinical development of biologics including interfaces with regulatory authorities worldwide. He is a senior executive with extensive therapeutic and commercial experience in global pharmaceutical and biotechnology companies. He has held professorships and maintained academic practices at the University of California, Davis and The Ohio State University.

Ruediger Jankowsk

Managing Director
Cinfa Biotech GmbH

Ruediger is the Managing D
biosimilar company of the Sp
appointed in 2014 with the go
the market for high-quality bios
Ruediger has built the operation
fully integrated level. Furthermo
the first biosimilar product car
stage. His responsibilities inclu
Biotech's product portfolio,
manufacturing and commercial
corporate strategy. Before he
was responsible for the global p
biosimilar development projects

SPOTLIGHT

BIOSIM

Adam Kautzner

Vice President, Formulary & Drug Trends Solutions
Express Scripts

Adam joined Express Scripts in 2008 as a clinical product manager. He also served as director of trend management and senior director of utilization management and formulary before being promoted to his current role in 2014. Adam has an excellent understanding of how their clients can blend a Drug Choices portfolio anchored by a formulary and utilization management strategy that addresses current needs while laying the foundation for the future. With the market rapidly evolving, especially within the specialty space, Adam has the foresight to keep clients nimble to quickly take advantage of these market changes or protect themselves from new waste developments. He ensures that their clients have this flexibility, but never at the expense of patient safety.

Cecil Nick

Vice President, Biotechnology
PAREXEL

Cecil has been working in regulatory affairs and clinical development for over 30 years; for the last 25 years focused on biological medicines. Particular expertise in monoclonals and biosimilars, having worked on over ten such programs and participated extensively in industry and international meetings on the subject.
He joined PAREXEL in February 2001 and has been involved with issues relating to clinical development, regulatory submissions, biosimilars, orphan drugs and training. In the last five years alone has worked on scores of clinical development plans connecting the input from pharmacologists, statisticians, therapeutic experts, and feasibility analyses to craft development plans which are effective, highly efficient and achievable with extensive experience in the field of inflammatory disease.

Michael Reilly

Executive Director
Alliance for Safe Biologic Med

ASBM is an organization of pa
and biotechnology companies
safety is at the forefront of the
since 2010. In that capacity Mr
white papers on biosimilars,
Health Organization and relea
data to the Spanish Health Mi
Ministry of Health in Rome.
the Associate Deputy Secret
of Health and Human Serv
responsible for policy develop
well as regulatory oversight for
Medicare and Medicaid Servic
Drug Administration (FDA). In
senior advisor to the Assistant
the Assistant Secretary for Pla
from 2002-2005.

For speaking opportunities please contact **Hannah Yate**

Steinar Madsen

Medical Director, Department of Drug Information
Norwegian Medicines Agency

Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency. He has been working with generic substitution since it was introduced in Norway in 2001 and with biosimilars since 2006. He is member and previously chairman of the committee for generic substitution at the Agency. Dr. Madsen is also engaged in the drug information service, with a special interest in the safe and cost-effective use of drugs. He is a specialist in internal medicine and cardiology and works part time as a consultant in cardiology.

Uwe Gudat

Head of Safety, Biosimilars
Merck

Uwe Gudat received his medical degree from the University of Marburg, Germany. He is licensed in internal medicine and diabetology as a sub-speciality, training under Michael Berger in Düsseldorf Germany. Uwe Gudat joined the pharmaceutical industry in 1995 with Eli Lilly and since then has held positions at Hesperion/Actelion, Novartis and Merck Serono. In this time he has led global clinical development teams, served as global medical brand director, led clinical teams for in-licensing due-diligence and managed clinical-trial review, first in man transitions and product safety assessments. Currently he is Head of Safety of the Merck Serono Biosimilars Unit. He has published a number of scientific papers in the field of diabetes and is currently on the editorial advisory board of Applied Clinical Trials.

WORLD
ILAR | CONGRESS
EUROPE 2016

ON SPEAKERS

Paul Chrisp

Programme Director, Medicines and Prescribing Centre
NICE

In his role at NICE, Paul is responsible for a comprehensive suite of guidance, advice and services for safe, efficient, high quality use of medicines. Paul led the development of NICE's position statement on biosimilars.
Paul has been with NICE since March 2009, where he was responsible for setting up the Institute's accreditation programme, which evaluates the processes used by organisations to develop guidance. Paul is a member of the Royal Pharmaceutical Society and spent over 20 years in international medical publishing and communications, mainly focusing on appraisal, review and synthesis of evidence to aid healthcare decision making and the adoption of new medicines.

Pierre Michetti

Gastroenterologist
Centre Hospitalier Universitaire Vaudois

Pierre Michetti, MD, is associate professor of medicine at the Faculty of Biology and Medicine, Lausanne University. He is past vice dean of the same faculty, past professor of medicine and past chief of the Division of Gastroenterology and Hepatology at the Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland. Currently he leads the Crohn's and Colitis Center at Clinique La Source, Lausanne.
Prof Michetti is a member of numerous scientific organizations with responsibilities such as the European Crohn's and Colitis Organisation, in which he served last as Scientific Officer in the Governing board and the United European Gastroenterology Federation Future Trends Committee.

DAY 1 – MONDAY 14 NOVEMBER, 2016

08:00 Registration opens

09:10 Chair's opening remarks
Steffen Thirstrup, Director, NDA Regulatory Advisory Board, **NDA Advisory Services**

BIOSIMILAR DEVELOPMENT FOR GLOBAL HEALTHCARE SYSTEMS

09:15 **Biosimilars uptake and market considerations in the EU**
- Biogen's experiences within the EU, and their joint venture with Samsung
- Biosimilars uptake in the EU – experience case study
- Impact of biosimilars for patients, HCPs and payers

Alpha Seth, Senior Vice President, Global Head of Biosimilars Business Unit, **Biogen**

09:35 **Critical quality attributes and extrapolation**
- Best practices to enable an abbreviated clinical programme based on the analytical characterisation and closeness of the biosimilar molecule to the originator
- Navigating global regulatory pathways with regards to critical quality attributes and extrapolation
- Clinical relevance of product quality attributes

Mark Levick, Global Head of Development, **Sandoz Biopharmaceuticals**

09:55 **Latest developments with the Norwegian study and the uptake of biosimilars in clinical practice**
- Hear the latest from the biosimilar studies coming out of Norway
- How has the data enabled the uptake, from a healthcare perspective?
- Lessons learnt from Norway that can be applied elsewhere to encourage greater uptake of biosimilars globally?

Steinar Madsen, Medical Director, Department of Drug Information, **Norwegian Medicines Agency**

10:15 **Outsourcing Biosimilars process development: a case study**
Monica Tello, Global Technical Manager (GTeM), Fast Trak, **GE Healthcare Life Sciences**

10:35 NETWORKING REFRESHMENT BREAK

11:35 **A holistic approach to technical and clinical development of biosimilars**
- Gain an understanding as to why technical development is key to biosimilar development and why it should be considered way before clinical development
- How do you then translate the technical findings to the clinical level?
- Best practices in implementing this concept to detect differences and enable appropriate product attributes

Ruediger Jankowsky, Managing Director, **Cinfa Biotech GmbH**

11:55 **Post-market assessment of biosimilars**
- Hear first-hand experience of evaluating the use and benefit-risk profile of biosimilars through an Italian healthcare database network
- What have been some of the challenges to do with data sources and methodology?
- What can be learnt on the effects of switching from this research?

Gianluca Trifirò, Assistant Professor of Pharmacology, **Erasmus Medical Center**

12:15 Speed Networking, **sponsored by Myoderm** MYODERM The Optimal Source

13:00 NETWORKING LUNCH BREAK

14:15 **Development considerations: Comparing major markets including US, EU, Japan and China**
- Hear different approaches to similarity of quality attributes
- Gain an understanding of navigating different clinical data requirements and their endpoints
- What are the requirements for choice of reference product, interchangeability, ethnicity and need for data from local patients, meeting with regulators and conducting global studies?

Cecil Nick, Vice President, Biotechnology, **PAREXEL**

PRICING DEBATE

14:35 PANEL: **Pricing Debate**

- Are biosimilars cost effective?
- What economic aspects need to be reviewed when it comes to biosimilars versus reference biologics?
- Lessons learnt from existing biosimilar approvals, both in the EU and the USA as well as in emerging markets, especially in terms of pricing and sustainability of the market
- What can biosimilar developers do to ensure favourable economics of their biosimilars during development?
- What are the incentives to switch?

Adam Kautzner, Vice President, Formulary & Drug Trends Solutions, **Express Scripts**
Asbjørn Mack, Chief Negotiator Pharmaceuticals, **Legemiddelinnkjøpssamarbeidet (LIS) – Drug Procurement Cooperation**

15:35 NETWORKING REFRESHMENT BREAK

CLINICAL RELEVANCE AND EXTRAPOLATION

16:15 **Current regulatory thinking on interchangeability of biosimilars**

- What is the EU perspective
- Will complete interchangeability ever be a reality?
- Nomenclature: Do we need a BQ scheme?

Pekka Kurki, Member of the Biosimlar Working Party, CHMP, **EMA;** Adjunct Professor, **University of Helsinki**

16:35 CASE STUDY: **NICE widens access of biosimilars to patients in England and Wales**

- Gain an understanding of NICE's approach to biosimilars
- What can be learnt from their recent recommendations in terms of the way they are approaching biosimilar approval and clinical use, including their views on patient involvement?
- What are NICE forecasting from biosimilars moving forward in terms of economics, availability and uptake?

Paul Chrisp, Programme Director, Medicines and Prescribing Centre, **NICE**

16:55 **Real world applications of extrapolation and the current state of interchangeability**

- Gain an understanding of the real world applications of extrapolation, with regards to immunogenicity and efficacy of extrapolation
- Review some recently published, established data on the topic
- Updates on the topic of interchangeability and the effect it is having on the industry's ability to design clinical trial to fulfil global guidelines

Bernd Liedert, Sr.Clinical Program Leader Biosimilars, **Boehringer Ingelheim**

17:15 PANEL: **The 'Indication Extrapolation Conundrum'**

- Following the USA's first biosimilar approval, what do we know about international practices regarding extrapolation?
- How can biosimilar developers best approach this challenge given different regulators are reviewing data differently, with different views on what is clinically meaningful?
- How does the notion of interchangeability affect the ongoing topic of extrapolation?

Bernd Liedert, Sr.Clinical Program Leader Biosimilars, **Boehringer Ingelheim**
Cecil Nick, Vice President, Biotechnology, **PAREXEL**
Jorge Santos da Silva, Principle, **McKinsey & Co.**

18:00 END OF DAY 1 – NETWORKING DRINKS RECEPTION

Want to get involved? Register your place today at **terrapinn.com/biosimilar16**

DAY 2 – TUESDAY 15 NOVEMBER, 2016

08:00 Registration opens

09:00 Recap of Day 1 and opening remarks for Day 2
Tony Williams, General Manager, **TWC Pharma Consulting**

CMC, PRECLINICAL AND CLINICAL CONSIDERATIONS FOR BIOSIMILARS

09:10

Is there a role for modelling and simulation in biosimilars development?

- Using modelling and simulation for clinical trial design
- Are models / simulations useful educational tools?
- What can modelling and simulation tell us about the emerging safety profile?

Uwe Gudat, Head of Safety, **Biosimilars, Merck**

09:30

Challenges in biosimilar bioanalytical assays and sample processing

- Hear about techniques for PK assay development and compound comparison for analytical similarity
- Gain insights into ADA assay development and sample measurement strategies in a special case
- Learn about automated sample analysis on biosimilars

René Wuttke, Bioanalytical Principal Investigator, Global Bioanalytical Services, **Celerion**

09:50

Practical considerations within biosimilar clinical development

- Building confidence in biosimilars: Biosimilarity vs. comparability
- How to make it all add up: Switching and why numbers matter

Rylan Hanks, Dir of Global Regulatory and R&D Policy, **Amgen** (Confirmed)

10:10

Multilevel state-of the art analytical methods for mAbs and Fc-fusion proteins biosimilarity assessment

- Insights of emerging 2D-LC-MS and HDX-MS methods
- Orthogonal chromatographic and electrophoretic methods hyphenated to Mass Spec
- FDA/EMA approved mAbs and biosimilars case studies

Alain Beck, Senior Director Analytical Chemistry, **CIPF and Associate Editor, mAbs**

10:25 NETWORKING REFRESHMENT BREAK

ROUNDTABLES: GLOBAL SUCCESS STORIES

11:25

Hear success stories from industry and academia on developing and commercialising biosimilars on a global scale. There will be at least 4 roundtables consisting of 2 rotations of 35 minutes allowing you to attend discussions on the 2 most pertinent topics for your business. Please see the website for more information on roundtable hosts.

Biosimilars in France

Morgane Beck, Pharmacist, OMEDIT **Alsace, Agence Régionale de Santé Alsace**

Biosimilars in Latin America

Wouter Verhoeven, Business Development Director **mAbxience**

Updating your bioprocess to accommodate biosimilars using the new resins from Mitsubishi Chemical

Alessio Piccoli, Sales Manager,**Resindion**

Future commercial model of biosimilar

Daniel Swann, Engagement Manager, **McKinsey & Co.**

Chris Eakins, Junior Partner, **McKinsey & Co.**

12.25 Round up remarks

12:40 NETWORKING REFRESHMENT BREAK

IMPLEMENTING BIOSIMILARS INTO THE MARKET

14:20

Developing biosimilars in an emerging market

- Hear an update on where Intas Biopharmaceuticals are with their biosimilar pipeline
- How do the regulatory and market access considerations differ in India compared to other global markets?
- What has the uptake of biosimilars been like from the healthcare sector in India?

Parisa Asvadi, AVP-Analytical Development and Global Regulatory Affairs Manager, **Intas Biopharmaceuticals**

14:40

How has our understanding of the system to ensure safe use of biosimilars changed?

- Implications of treatment pathways for assessing individual benefit/risk of a product
- State of readiness of healthcare technology for tracking biological products
- Update about clinical implications of immunogenicity and how impact can be measured
- Changing approach to regulatory requirements for risk management and what that means for biosimilars

Brian Edwards, Principal Consultant, **NDA Regulatory Science**

15:00

A year to review: 2016, more decisions, more launches, more unanswered questions

- Hear how the year has played out from a legal perspective
- What are we seeing from the US in terms of new decisions, new launches and their analysis of the data being submitted?
- Incorporating IPRs into biosimilar litigation strategies
- What impact is that having on the global biosimilar sector?

Tim Shea, Director, **Sterne, Kessler, Goldstein & Fox**

15:25

Obtaining patent protection while operating in an "anti-patent" climate

- Overview of recent cases affecting the biotechnology industry
- Impact on biosimilar development
- Strategies for obtaining adequate patent protection

Joanna Brougher, Biotech, Pharma and Medical Device IP and Corporate Counsel; Adjunct Lecturer, **Harvard School of Public Health**

15:40 — NETWORKING REFRESHMENT BREAK

16:30

The clinician's guide to biosimilar implementation

- Gain an overview of a clinician's perspective on biosimilars in the gastroenterology setting
- Views on switching patients from the originator to the biosimilar and examples of real life results in this area
- Insights into a biosimilar registry being set up in Switzerland to monitor patients and pharmacovigilance and what this means for clinician perspectives on biosimilars globally

Pierre Michetti, Gastroenterologist, **Centre Hospitalier Universitaire Vaudois**

16:50

PANEL: What are the mechanics required behind the implementation of biosimilars in the market?

- How important is post-market surveillance to implementing biosimilars in the market in the first place?
- Overview of the current situation pertaining to the global debate on naming of biosimilars
- How has USA's first biosimilar approval contributed to the debate on naming? What can we expect to see with this ongoing debate as we move closer to 2020?
- What role do collaborations and partnerships, including between academia and industry, play in the development of biosimilars?

Michael Reilly, Executive Director, **Alliance for Safe Biologic Medicines**

Pierre Michetti, Gastroenterologist, **Centre Hospitalier Universitaire Vaudois**

Kim Greco, Director of Research and Development Policy, **Amgen**

17:30 — END OF CONFERENCE – NETWORKING DRINKS RECEPTION

Want to get involved? Register your place today at **terrapinn.com/biosimilar16**

“GOOD SPEAKERS AND WELL RUN.”

VP, GLOBAL COMMERCIAL OPERATIONS | **EPIRUS BIOPHARMACEUTICALS**

THE CONGRESS AT A GLANCE

14TH NOVEMBER

WORLD BIOSIMILAR CONGRESS EUROPE 2016

- Biosimilar Development for Global Healthcare Systems
- Pricing Debate
- Clinical Relevance and Extrapolation

EUROPEAN ANTIBODY CONGRESS 2016

- Putting antibody development into the wider healthcare context
- Antibody-drug conjugates
- Target discover and computational biology
- Bispecific antibodies

WORLD IMMUNOTHERAPY CONGRESS 2016

- Approved Market Formats
- New Agents
- Combination Agents
- New Developments Formats and Receptors

15TH NOVEMBER

WORLD BIOSIMILAR CONGRESS EUROPE 2016

- CMC, Preclinical and ClinicalConsiderations for Biosimilars
- Global Success Stories
- Implementing Biosimilars into the Market

EUROPEAN ANTIBODY CONGRESS 2016

- Protein engineering
- Protein expression
- Analytics
- Immunogenicity and bioanalytics
- Immunotherapies

WORLD IMMUNOTHERAPY CONGRESS 2016

- Antigen Targets
- Cell Therapy for solid tumours
- Allogeneic gene therapy

16TH NOVEMBER

WORLD HPAPI CONGRESS 2016

- Handling and containment
- Processing
- Exposure risk mitigation
- Monitoring

EUROPEAN ANTIBODY CONGRESS 2016

- Platform technology showcase
- Clinical development
- CMC and developability
- Bioprocessing and production

WORLD IMMUNOTHERAPY CONGRESS 2016

- Oncolytic viral immunotherapies
- Vaccines

Want to get involved? Register your place today at **terrapinn.com/biosimilar16**

"GOOD CONGRESS TO CATCH UP WITH MAIN ISSUES RELATED TO DEVELOPMENT OF BIOSIMILARS. BI-PARTISAN DISCUSSIONS WERE VERY INFORMATIVE AS WELL. PRESENTATIONS WERE GREAT."

SENIOR PROJECT MANAGER,
MERCK KGAA | **MERCK GROUP GMBH**

THE EXHIBITION

WHO ATTENDS:

- Biosimilar developers
- Regulators
- Payers
- Clinicians and pharmacists
- Patient groups
- Academia
- Industry groups
- Finance & investment professionals



1	BioLegend
3a	Chemometec
6	LFB BioManufacturing
7	Resindion srl, a Mitsubishi Group Company
8	Retrogenix
9	CMC Biologics
10	Agilent Technologies
11	KBI Biopharma
13	Pall Life Sciences
14	Icosagen
15	PhyNexus, Inc
16	Eurofins BioPharma Product Testing

17	Aldevron
18	Quality Assistance
19	ALS
20	HEREAUS
21	Eurogentec-Kaneka
22	DEC
23	R-Pharm
24	Carbogen Amcis
25	Europa Bioproduct
26	NANOTEMPER
27	Protagen Protein Services GmbH
28	Synteract HCR
28A	Bio-Rad

29	DiscoverX
29A	Asterand Bioscience
30	Avact
31	Bucher Biotec / IntelliCyt CORP
33	FPS
34	Fujifilm Diosynth
35	Myoderm
36	Celerion
37	Bio-techne

WHO SPONSORS:

CROS

COMPARATIVE ANALYTICS

CMOS

PLATFORM TECHNOLOGY

LAW FIRMS

To learn more about how to exhibit, sponsor or speak at this year's event



SOURCING COMPANIES

MARKET ACCESS CONSULTANTS

REGULATORY CONSULTANTS

REGIONAL DEVELOPMENT ORGANISATIONS

WORLD BIOSIMILAR CONGRESS EUROPE 2016

t call **Andrew Li** on **+44(0)207 827 4150** or email **andrew.li@terrapinn.com**

SPONSORSHIP AND EXHIBITION PACKAGES

BENEFITS	PLATINUM	GOLD	SILVER	EXHIBITION
Keynote Presentation	1			
Track Presentation	1	1		
Roundtable Host	2	1	1	
Access to Networking Manager	Yes	Yes	Yes	
Delegate passes	6	3	2	Added on request
Exhibition booth	24 sqm	12 sqm	9 sqm	Purchased by sqm – 6 up to 24

Can't find a package that's right for you?
Talk to our team about tailoring something to meet your exact needs.

WORLD BIOSIMILAR CONGRESS EUROPE 2016
Andrew Li
+44 207 827 4150
andrew.li@terrapinn.com

EUROPEAN ANTIBODY CONGRESS 2016
Derek Cavanagh
+44 207 092 1297
derek.cavanagh@terrapinn.com

WORLD IMMUNOTHERAPY CONGRESS 2016
Derek Cavanagh
+44 207 092 1297
derek.cavanagh@terrapinn.com

WORLD HPAPI CONGRESS 2016
Toby Lomax
+44 207 092 1249
toby.lomax@terrapinn.com

2016 SPONSORS & EXHIBITORS

Gold Sponsor

NDA

Silver Sponsors

celerion
Applied Translational Medicine

GE

Bronze Sponsor

Resindion S.r.l.
A Subsidiary of MITSUBISHI CHEMICAL

Associate Sponsors

mAbxience
From lab to life

MYODERM
The Optimal Source

Sterne Kessler Goldstein Fox
ATTORNEYS AT LAW

TWC Pharma Consulting

Exhibitors

BIO-RAD
ALS
Agilent Technologies
aldevron
ASTERAND BIOSCIENCE
Avacta LIFE SCIENCES
BioLegend
biotechne
bucher biotec
CARBOGEN AMCIS
chemometec
CMC biologics
Dec Group
DiscoverX
eurofins
LFB BIOTECHNOLOGIES
EUROPA
FPS FOOD PHARMA SYSTEMS
FUJIFILM Diosynth biotechnologies
intellicyt
kaneka
KBI BIOPHARMA
nanoTEMPER technologies
forteBIO A Division of Pall Life Sciences
PhyNexus
PROTAGEN Protein Services
QUALITY ASSISTANCE Contract Research Organisation
R-PHARM Germany GmbH
RETROGENIX SPOTTING YOUR TARGET
SynteractHCR

Media Partners

BENTHAM SCIENCE
biosave Exceptional Savings for Life Scientists
BIOTECH GATE GLOBAL DATABASE
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
Farmavita Regulatory affairs network
GaBi GENERICS AND BIOSIMILARS INITIATIVE
Generics bulletin www.generics-bulletin.com
LABIOTECH.eu
iptechex pharmalicensing
MEDtube
Pharmaceutical-Tech.com
SWISS BIOTECH
TECHNOLOGY NETWORKS
The Cell Culture Dish
totalbiopharma

To learn more about how to exhibit, sponsor or speak at this year's event call
Andrew Li on **+44(0)207 827 4150** or email **andrew.li@terrapinn.com**

IT'S A NETWORKING EVENT

The World Biosimilar Congress recognises the importance of networking and offers an experience which allows you to do just that.

ROUNDTABLE DISCUSSIONS

With moderators to lead discussions on key topics, you will take your engagement and learnings to a new level in this interactive and results-driven setting.

NETWORKING RECEPTION

It's not always about the conference sessions. Our themed evening networking drinks receptions both at the conference venue and off-site on days one and two will allow you to unwind with your peers and continue conversations in good company.

NETWORKING LUNCHES

Our extended lunch periods will provide you with ample time to network between sessions. These lunch formats allow for more opportunities for casual conversations and introductions, without compromising your time attending the conference sessions.

SPEED NETWORKING

Sponsored by Myoderm, the Speed Networking session takes place on the morning of Day 1 enabling you to meet a variety of fellow conference delegates, some of whom you might not have met otherwise, and exchange business cards with the view to ultimately do business

Want to get involved? Register your place today at **terrapinn.com/biosimilar16**

WHO ATTENDS

XL Services Switzerland Ltd. Thai Food and Drug Administration Silapakorn University, Faculty of Pharmacy Epirus Biopharma Thai FDA Epirus Biopharmaceuticals, Inc. Genetika SAI Amgen Chemical Company of Malaysia Berhad Celonic A.G. Merck Group GmbH Alliance Boots Holdings 1 Ltd. Genzyme AS Mega Lifesciences Pty Ltd Banco Nacional De Desenvolvimento Economico E Social BIOLOTUS BIOTECH IMS Health Bispebjerg Hospital Private Group Practice Cinfa Biotech bioeq Boehringer Ingelheim Pharma GmbH & Co. KG Start-up Business Department Roche Quintiles GmbH Pfizer Roche Pharmaceuticals MSPharma Pharmascience Inc Biotechpharma U.A.B. PAREXEL Prescient Healthcare Group SGS-MScan SA N.D.A. Regulatory Science Ltd BioPharmaSpec Ltd Sterne Kessler Goldstein And Fox Plc NDA Group Myoderm Celltrion NDA Advisory Services Ltd Express Scripts TWC Pharma Consulting GmbH Merck Epirus Biopharmaceuticals Immune Deficiency Foundation Harvard School of Public Health University of Arizona College of Pharmacy Fujifilm Kyowa Kirin Biologics Health Products Regulatory Authority, Ireland Global Colon Cancer Association AGES Austrian Medicines and Medical Devices Agency Merck Serono Alliance for Safe Biologic Medicines Pall Corp Santa Farma Daiichi Sankyo Shenyang Sunshine Pharmaceutical Company Limited IMS Health Pfizer Canada Inc. Mundipharma SAI Chugai Pharmaceutical Co., Ltd. Roche a/s Inventiv Health Pfizer Ltd Selvita Sa Bispebjerg Hospital Genzyme AS Abbvie GK Duopharma (M) Sdn Bhd INC Research Promogen-MAB BioOutsource GASTROSAUDE Cinfa Proteros Biostructures Gmbh Bionical Ltd Bionical Ltd Merck Epirus Biopharma Novo Nordisk Pharmatech N.D.A. Regulatory Science Ltd R-Pharm Myoderm Asterand U.K. Sandoz Biopharmaceuticals NDA Advisory Services Ltd World Health Organisation Finnish Medicines Agency (FIMEA) Paul Ehrlich Institut AbbVie NDA Group Merck Serono R-Pharm Hokkaido University Graduate School Of Medicine University of Oslo Sandoz Anita Oconnor Consulting ProBioGen Amgen Hospira Hospira Myoderm FEF Chemicals Merck Merck Group GmbH

Want to get involved? Register your place today at **terrapinn.com/biosimilar16**

WHO ATTENDS

The earlier you book the more you'll save.

terrapinn.com/biosimilar16

Package	Before 26th AUG	Before 16th SEP	Before 7th OCT	Before 28th OCT	Final price
Standard package	€1870 **SAVE €700**	€2105 **SAVE €465**	€2340 **SAVE €230**	€2460 **SAVE €110**	€2570
Academic package	€940 **SAVE €350**	€1050 **SAVE €240**	€1170 **SAVE €120**	€1230 **SAVE €60**	€1290
Standard package for 3-5 people	€1685 **SAVE €630**	€1895 **SAVE €420**	€2105 **SAVE €1110**	€2215 **SAVE €100**	€2315
Academic and regulatory package for 3-5 people	€845 **SAVE €315**	€945 **SAVE €215**	€1055 **SAVE €105**	€1105 **SAVE €55**	€1160

If you are looking to bring 6 or more people in a group, please contact **Issa Mauthoor** on **+44 (0)207 092 1257** or **issa.mauthoor@terrapinn.com**